Abstract
Human immunodeficiency virus type 1 (HIV-1) infection is a chronic disease without
a known cure. The advent of effective antiretroviral therapy (ART) has enabled people
with HIV (PWH) to have significantly prolonged life expectancies. As a result, morbidity
and mortality associated with HIV-1 infection have declined considerably. However,
these individuals experience chronic systemic inflammation whose multifaceted etiology
is associated with other numerous comorbidities. Inflammasomes are vital mediators
that contribute to inflammatory signaling in HIV-1 infection. Here, we provide an
overview of the inflammatory pathway that underlies HIV-1 infection, explicitly highlighting
the role of the NLRP3 inflammasome. We also delineate the current literature on inflammasomes
and the therapeutic targeting strategies aimed at the NLRP3 inflammasome to moderate
HIV-1 infection-associated inflammation. Here we describe the NLRP3 inflammasome as
a key pathway in developing novel therapeutic targets to block HIV-1 replication and
HIV-1-associated inflammatory signaling. Controlling the inflammatory pathways is
critical in alleviating the morbidities and mortality associated with chronic HIV-1
infection in PWH.
Abbreviations:
HIV (human immunodeficiency virus), SIV (simian immunodeficiency virus), AIDS (acquired immune deficiency syndrome), CCR5 (chemokine receptor 5), CXCR4 (chemokine receptor 4), ART (antiretroviral), PWH (people with HIV), CTL (cytolytic T lymphocytes), Th (T helper), PD-1 (programmed cell death protein 1), LAG-3 (lymphocyte-activation gene 3), TIGIT (T cell immunoreceptor with Ig and ITIM domains), GALT (gut-associated lymphoid tissue), LPS (lipopolysaccharide), HCV (hepatitis C virus), HBV (hepatitis B virus), CMV (cytomegalovirus), PRR (pattern recognition receptor), ASC (apoptosis-associated speck-like protein containing a caspase-recruitment domain), NLR (NOD-like receptors), NACHT (central nucleotide-binding oligomerization), ALR (AIM2-like receptors), AIM2 (absent from melanoma 2), PAMP (pathogen-associated molecular pattern), DAMP (danger-associated molecular patterns)To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Translational ResearchAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Pneumocystis Pneumonia -- Los Angeles.MMWR. 1981; 30
- Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).Science. 1983; 220: 868-871https://doi.org/10.1126/science.6189183
- Human immunodeficiency virus (HIV).Transfus Med Hemother. 2016; 43: 203-222https://doi.org/10.1159/000445852
WHO. HIV data and statistics. 2022 Available at: https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hiv/strategic-information/hiv-data-and-statistics. Accessed 08/22/2022.
World Health Organization. HIV/AIDS. 2022. https://www.who.int/news-room/fact-sheets/detail/hiv-aids. Accessed 08/22/2022.
- NLRP3 inflammasome signaling as a link between HIV-1 infection and atherosclerotic cardiovascular disease.Front Cardiovasc Med. 2020; 7: 95https://doi.org/10.3389/fcvm.2020.00095
- Probing the interface of HIV and inflammaging.Curr HIV/AIDS Rep. 2021; 18: 198-210https://doi.org/10.1007/s11904-021-00547-0
- Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies.Lancet. 2008; 372: 293-299https://doi.org/10.1016/S0140-6736(08)61113-7
- Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.Prescrire Int. 2004; 13 (https://pubmed.ncbi.nlm.nih.gov/15532140/): 144-150
- HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty.J Gerontol A Biol Sci Med Sci. 2007; 62: 1279-1286https://doi.org/10.1093/gerona/62.11.1279
- What it means to age with HIV infection: years gained are not comorbidity free.JAMA Netw Open. 2020; 3e208023https://doi.org/10.1001/jamanetworkopen.2020.8023
- Aging, inflammation, and HIV infection.Top Antivir Med. 2012; 20: 101-105
- HIV infection, inflammation, immunosenescence, and aging.Annu Rev Med. 2011; 62: 141-155https://doi.org/10.1146/annurev-med-042909-093756
- Premature age-related comorbidities among HIV-infected persons compared with the general population.Clin Infect Dis. 2011; 53: 1120-1126https://doi.org/10.1093/cid/cir627
- HIV and aging: time for a new paradigm.Curr HIV/AIDS Rep. 2010; 7: 69-76https://doi.org/10.1007/s11904-010-0041-9
- Low-level HIV viremia is associated with microbial translocation and inflammation.J Acquir Immune Defic Syndr. 2013; 62: 129-134https://doi.org/10.1097/QAI.0b013e3182745ab0
- HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity.BMJ. 2009; 338: a3172https://doi.org/10.1136/bmj.a3172
- Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells.J Infect Dis. 2011; 204: 1217-1226https://doi.org/10.1093/infdis/jir507
- CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART.AIDS. 2010; 24: 959-968https://doi.org/10.1097/QAD.0b013e328337b957
- Residual inflammation and viral reservoirs: alliance against an HIV cure.Curr Opin HIV AIDS. 2016; 11: 234-241https://doi.org/10.1097/COH.0000000000000230
- T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy.J Infect Dis. 2003; 187: 1534-1543https://doi.org/10.1086/374786
- Early immune senescence in HIV disease.Curr HIV/AIDS Rep. 2010; 7: 4-10https://doi.org/10.1007/s11904-009-0038-4
- Immunologic biomarkers, morbidity, and mortality in treated HIV infection.J Infect Dis. 2016; 214: S44-S50https://doi.org/10.1093/infdis/jiw275
- Dissecting how CD4 T cells are lost during HIV infection.Cell Host Microbe. 2016; 19: 280-291https://doi.org/10.1016/j.chom.2016.02.012
- The Hitchhiker guide to CD4(+) T-cell depletion in lentiviral infection. A critical review of the dynamics of the CD4(+) T cells in SIV and HIV infection.Front Immunol. 2021; 12695674https://doi.org/10.3389/fimmu.2021.695674
- HIV-1-specific cytotoxicity is preferentially mediated by a subset of CD8(+) T cells producing both interferon-gamma and tumor necrosis factor-alpha.Blood. 2004; 104: 487-494https://doi.org/10.1182/blood-2003-12-4341
- CD8(+) T-cell response to HIV infection in the era of antiretroviral therapy.Front Immunol. 2019; 10: 1896https://doi.org/10.3389/fimmu.2019.01896
- The antibody response against HIV-1.Cold Spring Harb Perspect Med. 2012; 2a007039https://doi.org/10.1101/cshperspect.a007039
- Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.Annu Rev Immunol. 2000; 18: 665-708https://doi.org/10.1146/annurev.immunol.18.1.665
- Purinergic receptors: key mediators of HIV-1 infection and inflammation.Front Immunol. 2015; 6: 585https://doi.org/10.3389/fimmu.2015.00585
- HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation.Clin Infect Dis. 2012; 55: 126-136https://doi.org/10.1093/cid/cis406
- Low CD4+ T-cell counts in HIV patients receiving effective antiretroviral therapy are associated with CD4+ T-cell activation and senescence but not with lower effector memory T-cell function.Clin Immunol. 2006; 120: 163-170https://doi.org/10.1016/j.clim.2006.04.570
- Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.Proc Natl Acad Sci U S A. 2009; 106: 9403-9408https://doi.org/10.1073/pnas.0903107106
- Failure of combined antiretroviral therapy intensification with maraviroc and raltegravir in chronically HIV-1 infected patients to reduce the viral reservoir: the IntensHIV randomized trial.AIDS Res Ther. 2014; 11: 33https://doi.org/10.1186/1742-6405-11-33
- Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.AIDS. 2010; 24: 2451-2460https://doi.org/10.1097/QAD.0b013e32833ef7bb
- The upregulation of LAG-3 on T cells defines a subpopulation with functional exhaustion and correlates with disease progression in HIV-infected subjects.J Immunol. 2015; 194: 3873-3882https://doi.org/10.4049/jimmunol.1402176
- CD4+ T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART.PLoS Pathog. 2016; 12e1005761https://doi.org/10.1371/journal.ppat.1005761
- The paradox of the immune response in HIV infection: when inflammation becomes harmful.Clin Chim Acta. 2013; 416: 96-99https://doi.org/10.1016/j.cca.2012.11.025
- Abortive HIV infection mediates CD4 T cell depletion and inflammation in human lymphoid tissue.Cell. 2010; 143 (In English): 789-801https://doi.org/10.1016/j.cell.2010.11.001
- Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection.Nature. 2014; 505 (In English): 509-514https://doi.org/10.1038/nature12940
- Cell-to-cell transmission of HIV-1 is required to trigger pyroptotic death of lymphoid-tissue-derived CD4 T cells.Cell Rep. 2015; 12 (In English): 1555-1563https://doi.org/10.1016/j.celrep.2015.08.011
- IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV.Science. 2014; 343 (In English): 428-432https://doi.org/10.1126/science.1243640
- Blood-derived CD4 T cells naturally resist pyroptosis during abortive HIV-1 infection.Cell Host Microbe. 2015; 18 (In English): 463-470https://doi.org/10.1016/j.chom.2015.09.010
- Gut microbiome homeostasis and the CD4 T- follicular helper cell IgA axis in human immunodeficiency virus infection.Front Immunol. 2021; 12657679https://doi.org/10.3389/fimmu.2021.657679
- Microbial translocation is a cause of systemic immune activation in chronic HIV infection.Nat Med. 2006; 12: 1365-1371https://doi.org/10.1038/nm1511
- Immune activation and HIV persistence: implications for curative approaches to HIV infection.Immunol Rev. 2013; 254: 326-342https://doi.org/10.1111/imr.12065
- Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection.J Infect Dis. 2010; 201: 1788-1795https://doi.org/10.1086/652749
- Persistent, albeit reduced, chronic inflammation in persons starting antiretroviral therapy in acute HIV infection.Clin Infect Dis. 2017; 64: 124-131https://doi.org/10.1093/cid/ciw683
- Circulating LPS and (1–>3)-beta-D-Glucan: a Folie a Deux contributing to HIV-associated immune activation.Front Immunol. 2019; 10: 465https://doi.org/10.3389/fimmu.2019.00465
- Increased levels of systemic LPS-positive bacterial extracellular vesicles in patients with intestinal barrier dysfunction.Gut. 2020; 69: 191-193https://doi.org/10.1136/gutjnl-2018-317726
- HIV persistence in the gut mucosa of HIV-infected subjects undergoing antiretroviral therapy correlates with immune activation and increased levels of LPS.Curr HIV Res. 2011; 9: 148-153https://doi.org/10.2174/157016211795945296
- Fecal microbiota composition drives immune activation in HIV-infected individuals.EBioMedicine. 2018; 30: 192-202https://doi.org/10.1016/j.ebiom.2018.03.024
- The mucosal barrier and immune activation in HIV pathogenesis.Curr Opin HIV AIDS. 2008; 3: 356-361https://doi.org/10.1097/COH.0b013e3282f9ae9c
- Microbial translocation and inflammation occur in hyperacute immunodeficiency virus infection and compromise host control of virus replication.PLoS Pathog. 2016; 12e1006048https://doi.org/10.1371/journal.ppat.1006048
- Purinergic receptors: elucidating the role of these immune mediators in HIV-1 fusion.Viruses. 2020; 12: 290https://doi.org/10.3390/v12030290
- P2X1 selective antagonists block HIV-1 infection through inhibition of envelope conformation-dependent fusion.J Virol. 2020; 94: e01622-19https://doi.org/10.1128/JVI.01622-19
- P2X-selective purinergic antagonists are strong inhibitors of HIV-1 fusion during both cell-to-cell and cell-free infection.J Virol. 2014; 88: 11504-11515https://doi.org/10.1128/JVI.01158-14
- P2RX7 at the host-pathogen interface of infectious diseases.Microbiol Mol Biol Rev. 2021; 85: e00055-20–20https://doi.org/10.1128/MMBR.00055-20
- Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection.J Infect Dis. 2014; 210: 1228-1238https://doi.org/10.1093/infdis/jiu238
- CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.J Exp Med. 2004; 200: 749-759https://doi.org/10.1084/jem.20040874
- HIV disease: fallout from a mucosal catastrophe?.Nat Immunol. 2006; 7: 235-239https://doi.org/10.1038/ni1316
- Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract.J Exp Med. 2004; 200: 761-770https://doi.org/10.1084/jem.20041196
- Replication of CMV in the gut of HIV-infected individuals and epithelial barrier dysfunction.PLoS Pathog. 2017; 13e1006202https://doi.org/10.1371/journal.ppat.1006202
- Immune activation response in chronic HIV-infected patients: influence of hepatitis C virus coinfection.PLoS One. 2015; 10e0119568https://doi.org/10.1371/journal.pone.0119568
- Role of inflammasomes in HIV-1 and drug abuse mediated neuroinflammaging.Cells. 2020; 9: 1857https://doi.org/10.3390/cells9081857
- HIV-1 and drug abuse comorbidity: lessons learned from the animal models of NeuroHIV.Neurosci Lett. 2021; 754135863https://doi.org/10.1016/j.neulet.2021.135863
- HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use.AIDS Care. 2009; 21: 655-663https://doi.org/10.1080/09540120802459762
- Imaging studies of the HIV-infected brain.Handb Clin Neurol. 2018; 152: 229-264https://doi.org/10.1016/B978-0-444-63849-6.00018-9
- Effect of cocaine on HIV infection and inflammasome gene expression profile in HIV infected macrophages.Sci Rep. 2016; 6: 27864https://doi.org/10.1038/srep27864
- Inflammasome in drug abuse.Int J Physiol Pathophysiol Pharmacol. 2017; 9: 165-177
- HIV-1 tat primes and activates microglial NLRP3 inflammasome-mediated neuroinflammation.J Neurosci. 2017; 37: 3599-3609https://doi.org/10.1523/JNEUROSCI.3045-16.2017
- HIV-1 viral protein R activates NLRP3 inflammasome in microglia: implications for HIV-1 associated neuroinflammation.J Neuroimmune Pharmacol. 2017; 12: 233-248https://doi.org/10.1007/s11481-016-9708-3
- Rapid inflammasome activation in microglia contributes to brain disease in HIV/AIDS.Retrovirology. 2014; 11: 35https://doi.org/10.1186/1742-4690-11-35
- Serious non-AIDS events: therapeutic targets of immune activation and chronic inflammation in HIV infection.Drugs. 2016; 76: 533-549https://doi.org/10.1007/s40265-016-0546-7
- Effect of probiotics (Saccharomyces boulardii) on microbial translocation and inflammation in HIV-treated patients: a double-blind, randomized, placebo-controlled trial.J Acquir Immune Defic Syndr. 2015; 68: 256-263https://doi.org/10.1097/QAI.0000000000000468
- Omega-3 fatty acid therapy reduces triglycerides and interleukin-6 in hypertriglyeridemic HIV patients.HIV Med. 2013; 14: 530-539https://doi.org/10.1111/hiv.12046
- The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta.Mol Cell. 2002; 10: 417-426https://doi.org/10.1016/s1097-2765(02)00599-3
- Inflammasomes: mechanism of action, role in disease, and therapeutics.Nat Med. 2015; 21: 677-687https://doi.org/10.1038/nm.3893
- Inflammasome complexes: emerging mechanisms and effector functions.Cell. 2016; 165: 792-800https://doi.org/10.1016/j.cell.2016.03.046
- Inflammasomes.Cold Spring Harb Perspect Biol. 2014; 6a016287https://doi.org/10.1101/cshperspect.a016287
- Function of Nod-like receptors in microbial recognition and host defense.Immunol Rev. 2009; 227: 106-128https://doi.org/10.1111/j.1600-065X.2008.00734.x
- Inflammasome activation and regulation: toward a better understanding of complex mechanisms.Cell Discov. 2020; 6: 36https://doi.org/10.1038/s41421-020-0167-x
- The inflammasomes.Cell. 2010; 140: 821-832https://doi.org/10.1016/j.cell.2010.01.040
- Recent insights on inflammasomes, gasdermin pores, and pyroptosis.Cold Spring Harb Perspect Biol. 2020; 12: a036392https://doi.org/10.1101/cshperspect.a036392
- The NLR gene family: a standard nomenclature.Immunity. 2008; 28: 285-287https://doi.org/10.1016/j.immuni.2008.02.005
- Inflammasomes: mechanism of assembly, regulation and signalling.Nat Rev Immunol. 2016; 16 (In English): 407-420https://doi.org/10.1038/nri.2016.58
- Caspase-4 mediates non-canonical activation of the NLRP3 inflammasome in human myeloid cells.Eur J Immunol. 2015; 45: 2911-2917https://doi.org/10.1002/eji.201545523
- ATP-binding and hydrolysis in inflammasome activation.Molecules. 2020; 25 (In English)https://doi.org/10.3390/molecules25194572
- The role of inflammasome activation in early HIV infection.J Immunol Res. 2021; 2021 (In English)1487287https://doi.org/10.1155/2021/1487287
- The interplay between viruses and host DNA sensors.Viruses. 2022; 14 (In English)https://doi.org/10.3390/v14040666
- Toll-like receptor (TLR) signaling enables cyclic GMP-AMP synthase (cGAS) sensing of HIV-1 Infection in macrophages.mBio. 2021; 12 (In English)e0281721https://doi.org/10.1128/mBio.02817-21
- Sensor sensibility-HIV-1 and the innate immune response.Cells. 2020; 9 (In English): 254https://doi.org/10.3390/cells9010254
- An update on cell intrinsic negative regulators of the NLRP3 inflammasome.J Leukoc Biol. 2018; 103 (In English): 1165-1177https://doi.org/10.1002/JLB.3MIR0917-350R
- Self-DNA sensing fuels HIV-1-associated inflammation.Trends Mol Med. 2019; 25 (In English): 941-954https://doi.org/10.1016/j.molmed.2019.06.004
- Nucleic acid sensing in mammals and plants: facts and caveats.Int Rev Cell Mol Biol. 2019; 345 (In English): 225-285https://doi.org/10.1016/bs.ircmb.2018.10.003
- The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis.Nat Immunol. 2009; 10: 241-247https://doi.org/10.1038/ni.1703
- The NLRP3 inflammasome: an overview of mechanisms of activation and regulation.Int J Mol Sci. 2019; 20: 3328https://doi.org/10.3390/ijms20133328
- NLRP3 inflammasome in neurological diseases, from functions to therapies.Front Cell Neurosci. 2017; 11: 63https://doi.org/10.3389/fncel.2017.00063
- The intersection of cell death and inflammasome activation.Cell Mol Life Sci. 2016; 73 (In English): 2349-2367https://doi.org/10.1007/s00018-016-2205-2
- Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death.Nature. 2015; 526 (In English): 660-665https://doi.org/10.1038/nature15514
- Caspase-11 cleaves gasdermin D for non-canonical inflammasome signalling.Nature. 2015; 526 (In English): 666-671https://doi.org/10.1038/nature15541
- HIV in the brain: identifying viral reservoirs and addressing the challenges of an HIV cure.Vaccines (Basel). 2021; 9: 867https://doi.org/10.3390/vaccines9080867
- Inflammasomes in the CNS.Nat Rev Neurosci. 2014; 15: 84-97https://doi.org/10.1038/nrn3638
- The NLRP3 inflammasome is upregulated in HIV-infected antiretroviral therapy-treated individuals with defective immune recovery.Front Immunol. 2018; 9: 214https://doi.org/10.3389/fimmu.2018.00214
- HIV-1 induces the first signal to activate the NLRP3 inflammasome in monocyte-derived macrophages.Intervirology. 2014; 57: 36-42https://doi.org/10.1159/000353902
- Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors.Cell Death Dis. 2019; 10: 128https://doi.org/10.1038/s41419-019-1413-8
- Role of inflammasomes in HIV-1 infection and treatment.Trends Mol Med. 2022; 28 (In English): 421-434https://doi.org/10.1016/j.molmed.2022.02.010
- HIV-1 Gag and Vpr impair the inflammasome activation and contribute to the establishment of chronic infection in human primary macrophages.Mol Immunol. 2022; 148 (In English): 68-80https://doi.org/10.1016/j.molimm.2022.04.018
- Ligand-gated purinergic receptors regulate HIV-1 tat and morphine related neurotoxicity in primary mouse striatal neuron-glia co-cultures.J Neuroimmun Pharmacol. 2014; 9: 233-244https://doi.org/10.1007/s11481-013-9507-z
- Adenosine triphosphate released from HIV-infected macrophages regulates glutamatergic tone and dendritic spine density on neurons.J Neuroimmun Pharmacol. 2013; 8: 998-1009https://doi.org/10.1007/s11481-013-9471-7
- Purinergic receptors are required for HIV-1 infection of primary human macrophages.J Immunol. 2012; 188 (Research Support, N.I.H., Extramural) (In English)): 4488-4495https://doi.org/10.4049/jimmunol.1102482
- Extracellular ATP induces the rapid release of HIV-1 from virus containing compartments of human macrophages.Proc Natl Acad Sci U S A. 2015; 112: E3265-E3273https://doi.org/10.1073/pnas.1500656112
- Extracellular ATP acts on P2Y2 purinergic receptors to facilitate HIV-1 infection.J Exp Med. 2011; 208: 1823-1834https://doi.org/10.1084/jem.20101805
- HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse.J Exp Med. 2004; 199 (In English): 283-293https://doi.org/10.1084/jem.20030648
- Sequence of human immunodeficiency virus type 1 (HIV-1) Gag localization and oligomerization monitored with live confocal imaging of a replication-competent, fluorescently tagged HIV-1.J Virol. 2007; 81 (Research Support, N.I.H., Extramural): 12596-12607
Research Support, U.S. Gov't, Non-P.H.S.) (In English). 2022. DOI: 10.1128/JVI.01088-07. Sequence of Human Immunodeficiency Virus Type 1 (HIV-1) Gag Localization and Oligomerization Monitored with Live Confocal Imaging of a Replication-Competent, Fluorescently Tagged HIV-1 https://journals.asm.org/doi/10.1128/JVI.01088-07?cookieSet=1
- High-throughput HIV-cell fusion assay for discovery of virus entry inhibitors.Assay Drug Dev Technol. 2015; 13: 155-166https://doi.org/10.1089/adt.2015.639
- P2X1 receptor antagonists inhibit HIV-1 fusion by blocking virus-coreceptor interactions.J Virol. 2015; 89: 9368-9382https://doi.org/10.1128/JVI.01178-15
- P2X antagonists inhibit HIV-1 productive infection and inflammatory cytokines interleukin-10 (IL-10) and IL-1β in a human tonsil explant model.J Virol. 2019; 93 (10e01186-18(In English))https://doi.org/10.1128/JVI.01186-18
- Pannexin1 hemichannels are critical for HIV infection of human primary CD4+ T lymphocytes.J Leukoc Biol. 2013; 94 (Research Support, N.I.H., Extramural) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3747: 399-407
Research Support, Non-U.S. Gov't). 2022. DOI: 10.1189/jlb.0512249.
- Editorial: pannexin-1—the hidden gatekeeper for HIV-1.J Leukoc Biol. 2013; 94: 390-392https://doi.org/10.1189/jlb.0313148
- Cell-to-cell transmission of HIV-1 is required to trigger pyroptotic death of lymphoid-tissue-derived CD4 T cells.Cell Rep. 2015; 12 (In English): 1555-1563https://doi.org/10.1016/j.celrep.2015.08.011
- Blood-derived CD4 T cells naturally resist pyroptosis during abortive HIV-1 infection.Cell Host Microbe. 2015; 18 (In English): 463-470https://doi.org/10.1016/j.chom.2015.09.010
- Next-generation mRNA sequencing reveals pyroptosis-induced CD4+ T cell death in early simian immunodeficiency virus-infected lymphoid tissues.J Virol. 2016; 90 (In English): 1080-1087https://doi.org/10.1128/JVI.02297-15
- Polymorphism in IFI16 affects CD4(+) T-cell counts in HIV-1 infection.Int J Immunogenet. 2014; 41 (In English): 518-520https://doi.org/10.1111/iji.12157
- Innate DNA sensing is impaired in HIV patients and IFI16 expression correlates with chronic immune activation.Clin Exp Immunol. 2014; 177 (In English): 295-309https://doi.org/10.1111/cei.12317
- Restriction factors expression decreases in HIV-1 patients after cART.New Microbiol. 2021; 44 (In English): 95-103
- IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication.Proc Natl Acad Sci U S A. 2013; 110 (In English): E4571-E4580https://doi.org/10.1073/pnas.1311669110
- Cellular factors targeting HIV-1 transcription and Viral RNA transcripts.Viruses. 2020; 12 (In English)https://doi.org/10.3390/v12050495
- IFI16 knockdown in primary HIV-1 target cells.STAR Protoc. 2021; 2 (In English)100236https://doi.org/10.1016/j.xpro.2020.100236
- Nuclear PYHIN proteins target the host transcription factor Sp1 thereby restricting HIV-1 in human macrophages and CD4+ T cells.PLoS Pathog. 2020; 16 (In English)e1008752https://doi.org/10.1371/journal.ppat.1008752
- IFI16 targets the transcription factor Sp1 to suppress HIV-1 transcription and latency reactivation.Cell Host Microbe. 2019; 25 (e13. (In English)): 858-872https://doi.org/10.1016/j.chom.2019.05.002
- Susceptibility to Mycobacterium tuberculosis infection in HIV-positive patients is associated with CARD8 genetic variant.J Acquir Immune Defic Syndr. 2013; 63 (In English): 147-151https://doi.org/10.1097/QAI.0b013e31828f93bb
- Polymorphisms in inflammasome' genes and susceptibility to HIV-1 infection.J Acquir Immune Defic Syndr. 2012; 59 (In English): 121-125https://doi.org/10.1097/QAI.0b013e3182392ebe
- CARD8 is an inflammasome sensor for HIV-1 protease activity.Science. 2021; 371 (In English)https://doi.org/10.1126/science.abe1707
- Beyond inhibition: a novel strategy of targeting HIV-1 protease to eliminate viral reservoirs.Viruses. 2022; 14 (In English)https://doi.org/10.3390/v14061179
- HIV replication is associated to inflammasomes activation, IL-1β, IL-18 and caspase-1 expression in GALT and peripheral blood.PLoS One. 2018; 13 (In English)e0192845https://doi.org/10.1371/journal.pone.0192845
- Human NLRP1 is a sensor for double-stranded RNA.Science. 2021; 371 (In English)https://doi.org/10.1126/science.abd0811
- Landscape of T cells transcriptional and metabolic modules during HIV infection based on weighted gene co-expression network analysis.Front Genet. 2021; 12 (In English)756471https://doi.org/10.3389/fgene.2021.756471
- Flagellin/NLRC4 pathway rescues NLRP3-inflammasome defect in dendritic cells from HIV-infected patients: perspective for new adjuvant in immunocompromised individuals.Front Immunol. 2019; 10 (In English): 1291https://doi.org/10.3389/fimmu.2019.01291
- DNA-encoded flagellin activates toll-like receptor 5 (TLR5), Nod-like receptor family CARD domain-containing protein 4 (NRLC4), and acts as an epidermal, systemic, and mucosal-adjuvant.Vaccines (Basel). 2013; 1 (In English): 415-443https://doi.org/10.3390/vaccines1040415
- A common NLRC4 gene variant associates with inflammation and pulmonary function in human immunodeficiency virus and tuberculosis.Clin Infect Dis. 2020; 71 (In English): 924-932https://doi.org/10.1093/cid/ciz898
- Differential recognition of HIV-stimulated IL-1β and IL-18 secretion through NLR and NAIP signalling in monocyte-derived macrophages.PLoS Pathog. 2021; 17 (In English)e1009417https://doi.org/10.1371/journal.ppat.1009417
- AIM2 inflammasome is activated by pharmacological disruption of nuclear envelope integrity.Proc Natl Acad Sci U S A. 2016; 113 (In English): E4671-E4680https://doi.org/10.1073/pnas.1602419113
- Pharmacological inhibitors of the NLRP3 inflammasome.Front Immunol. 2019; 10: 2538https://doi.org/10.3389/fimmu.2019.02538
- NLRP3 inflammasome and its inhibitors: a review.Front Pharmacol. 2015; 6 (In English): 262https://doi.org/10.3389/fphar.2015.00262
- A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.Nat Med. 2015; 21: 248-255https://doi.org/10.1038/nm.3806
- NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses.J Immunol. 2010; 185: 974-981https://doi.org/10.4049/jimmunol.0904145
- Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders.J Exp Med. 2017; 214: 3219-3238https://doi.org/10.1084/jem.20171419
- 3,4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome.J Biol Chem. 2014; 289 (In English): 1142-1150https://doi.org/10.1074/jbc.M113.515080
- OLT1177, a beta-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation.Proc Natl Acad Sci U S A. 2018; 115: E1530-E1539https://doi.org/10.1073/pnas.1716095115
- Tranilast directly targets NLRP3 to treat inflammasome-driven diseases.EMBO Mol Med. 2018; 10: e8689https://doi.org/10.15252/emmm.201708689
- Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity.Nat Commun. 2018; 9: 2550https://doi.org/10.1038/s41467-018-04947-6
- ATP-sensitive potassium channelopathies: focus on insulin secretion.J Clin Invest. 2005; 115: 2047-2058https://doi.org/10.1172/JCI25495
- Glyburide inhibits the cryopyrin/Nalp3 inflammasome.J Cell Biol. 2009; 187: 61-70https://doi.org/10.1083/jcb.200903124
- A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome.Biochem Pharmacol. 2013; 85 (In English): 1504-1512https://doi.org/10.1016/j.bcp.2013.03.008
- Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study].Am J Cardiol. 2013; 111: 1394-1400https://doi.org/10.1016/j.amjcard.2013.01.287
- Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse.Eur J Heart Fail. 2010; 12: 319-322https://doi.org/10.1093/eurjhf/hfq017
- Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases.Basic Res Cardiol. 2017; 113: 5https://doi.org/10.1007/s00395-017-0663-9
- Antiinflammatory therapy with canakinumab for atherosclerotic disease.N Engl J Med. 2017; 377: 1119-1131https://doi.org/10.1056/NEJMoa1707914
- The CB2 receptor and its role as a regulator of inflammation.Cell Mol Life Sci. 2016; 73 (In English): 4449-4470https://doi.org/10.1007/s00018-016-2300-4
- Endocannabinoid system components: overview and tissue distribution.Adv Exp Med Biol. 2019; 1162 (In English): 1-12https://doi.org/10.1007/978-3-030-21737-2_1
- Selective activation of cannabinoid receptor 2 attenuates myocardial infarction via suppressing NLRP3 inflammasome.Inflammation. 2019; 42: 904-914https://doi.org/10.1007/s10753-018-0945-x
- Activation of cannabinoid receptor 2 ameliorates DSS-induced colitis through inhibiting NLRP3 inflammasome in macrophages.PLoS One. 2016; 11e0155076https://doi.org/10.1371/journal.pone.0155076
- Activation of cannabinoid receptor type 2 attenuates surgery-induced cognitive impairment in mice through anti-inflammatory activity.J Neuroinflammation. 2017; 14 (In English): 138https://doi.org/10.1186/s12974-017-0913-7
- Cannabidiol modulates the immunophenotype and inhibits the activation of the inflammasome in human gingival mesenchymal stem cells.Front Physiol. 2016; 7 (In English): 559https://doi.org/10.3389/fphys.2016.00559
- Cannabinoid receptor 2-mediated attenuation of CXCR4-tropic HIV infection in primary CD4+ T cells.PLoS One. 2012; 7 (In English): e33961https://doi.org/10.1371/journal.pone.0033961
- Probable deceleration of progression of Simian AIDS affected by opiate dependency: studies with a rhesus macaque/SIVsmm9 model.J Acquir Immune Defic Syndr. 2009; 50 (In English): 241-249https://doi.org/10.1097/QAI.0b013e3181967354
- Cannabinoid inhibition of macrophage migration to the trans-activating (Tat) protein of HIV-1 is linked to the CB(2) cannabinoid receptor.J Pharmacol Exp Ther. 2010; 333: 319-327https://doi.org/10.1124/jpet.109.163055
- Cannabinoids and inflammation: implications for people living with HIV.AIDS. 2019; 33: 2273-2288https://doi.org/10.1097/QAD.0000000000002345
Article Info
Publication History
Published online: July 30, 2022
Accepted:
July 27,
2022
Received in revised form:
July 23,
2022
Received:
June 2,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2022 Elsevier Inc. All rights reserved.
